Shopping Cart 0
Cart Subtotal
USD 0

Eiger BioPharmaceuticals Inc (EIGR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Eiger BioPharmaceuticals Inc (Eiger), formerly Celladon Corp is a clinical-stage biopharmaceutical company that focuses on the development and commercializationof novel drugs for the treatment of orphan diseases. The company provides pipeline products such as Lonafarnib and Lambda, which are in Phase 2 trials used for the treatment of hepatitis delta virusinfection; Exendin 9-39, a phase 2 program for post-bariatric hypoglycemia;Ubenimex, a phase 2 program for lymphedema and pulmonary arterial hypertension. It offers late-stage portfolio products candidates that potential to address diseases for which unmet medical services. Eiger provides clinical development and commercialization of broad range of therapeutics. The company offers post bariatric hypogiycemia prevention services. Eiger is headquartered in Palo Alto, California, the US.

Eiger BioPharmaceuticals Inc (EIGR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Eiger BioPharma Acquires Assets and Rights to exendin 9-39 from Tracey McLaughlin and Colleen Craig 12

Venture Financing 13

Eiger BioPharma Raises USD3 Million in Venture Financing 13

Celladon Raises USD3 Million in Venture Financing 14

Eiger BioPharma Raises USD6 Million in Venture Financing 15

Eiger Biopharma Raises USD 1 Million In Third Tranche Of Series A Financing 16

Partnerships 17

Eiger BioPharma Enters into Collaboration Agreement with Progeria Research 17

Merger 18

Eiger BioPharma Merges with Celladon 18

Licensing Agreements 20

Eiger BioPharmaceuticals Enters into Licensing Agreement with Bristol-Myers Squibb 20

Eiger BioPharma Enters into Licensing Agreement with Stanford University for Post-Bariatric Surgical Hypoglycemia 21

Eiger BioPharma Enters into Licensing Agreement with Stanford University 22

Eiger BioPharma Enters into Licensing Agreement with Stanford University for Pulmonary Arterial Hypertension 23

Eiger BioPharma Enters into Licensing Agreement with Nippon Kayaku 24

Eiger BioPharma Enters into Licensing Agreement with Janssen Pharma for Tipifarnib 25

Equity Offering 26

Eiger BioPharma Prices Public Offering of Shares for USD40 Million 26

Eiger BioPharma Raises USD18.5 Million in Public Offering of Shares 28

Eiger BioPharma Raises USD20 Million in Public Offering of Shares 30

Eiger BioPharma Plans to Raise up to USD25 Million in Public Offering of Shares 32

Eiger BioPharma Raises USD39.5 Million in Private Placement of Shares 33

Asset Transactions 35

Eiger BioPharma Sells Mydicar to Theragene Pharma 35

Eiger BioPharmaceuticals Inc-Key Competitors 36

Eiger BioPharmaceuticals Inc-Key Employees 37

Eiger BioPharmaceuticals Inc-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 39

Financial Announcements 39

Aug 10, 2018: Eiger Biopharmaceuticals announces second quarter 2018 financial results 39

May 11, 2018: Eiger BioPharmaceuticals Reports First Quarter 2018 Financial Results 40

Mar 12, 2018: Eiger BioPharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results 41

Nov 09, 2017: Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results 42

Aug 14, 2017: Eiger BioPharmaceuticals Reports Second Quarter 2017 Financial Results 44

May 12, 2017: Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results 45

Mar 23, 2017: Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results 47

Corporate Communications 49

Jan 08, 2018: Eiger BioPharmaceuticals Announces Appointment of Commercial Operations Industry Veteran Eldon Mayer to its Board of Directors 49

Jan 03, 2018: Eiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA Chief Operating Officer and Executive Medical Officer 50

Sep 18, 2017: Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors 51

Jun 14, 2017: Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors 52

Apr 18, 2017: Eiger BioPharmaceuticals appoints new lead for development of PBH treatment 53

Product News 54

04/18/2017: Eiger Announces Industry Veteran Lisa Porter, M.D. to Lead Development of Exendin 9-39 for the Treatment of Post-Bariatric Hypoglycemia 54

Product Approvals 55

Sep 05, 2017: Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection 55

Jul 27, 2017: Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection 56

May 03, 2017: Eiger Announces U.S. IND Filing of Pegylated Interferon Lambda for Hepatitis Delta Virus Infection -LIMT HDV: Lambda Interferon MonoTherapy in HDV Study Enrolling 57

Clinical Trials 58

Aug 14, 2018: Eiger BioPharmaceuticals completes enrolment in Prevent trial 58

Mar 26, 2018: Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia 59

Oct 23, 2017: Eiger Announces Positive Phase 2 Interim 24-Week Data with Pegylated Interferon Lambda in Hepatitis Delta Virus Infection at the American Association for the Study of Liver Diseases Meeting 60

Oct 02, 2017: Eiger Announces Presentation on Lambda at the American Association for the Study of Liver Diseases Meeting 61

Jul 24, 2017: Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection 62

Jun 12, 2017: Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego 63

Jun 06, 2017: Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients 65

Appendix 66

Methodology 66

About GlobalData 66

Contact Us 66

Disclaimer 66


List Of Figure

List of Figures

Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Eiger BioPharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Eiger BioPharma Acquires Assets and Rights to exendin 9-39 from Tracey McLaughlin and Colleen Craig 12

Eiger BioPharma Raises USD3 Million in Venture Financing 13

Celladon Raises USD3 Million in Venture Financing 14

Eiger BioPharma Raises USD6 Million in Venture Financing 15

Eiger Biopharma Raises USD 1 Million In Third Tranche Of Series A Financing 16

Eiger BioPharma Enters into Collaboration Agreement with Progeria Research 17

Eiger BioPharma Merges with Celladon 18

Eiger BioPharmaceuticals Enters into Licensing Agreement with Bristol-Myers Squibb 20

Eiger BioPharma Enters into Licensing Agreement with Stanford University for Post-Bariatric Surgical Hypoglycemia 21

Eiger BioPharma Enters into Licensing Agreement with Stanford University 22

Eiger BioPharma Enters into Licensing Agreement with Stanford University for Pulmonary Arterial Hypertension 23

Eiger BioPharma Enters into Licensing Agreement with Nippon Kayaku 24

Eiger BioPharma Enters into Licensing Agreement with Janssen Pharma for Tipifarnib 25

Eiger BioPharma Prices Public Offering of Shares for USD40 Million 26

Eiger BioPharma Raises USD18.5 Million in Public Offering of Shares 28

Eiger BioPharma Raises USD20 Million in Public Offering of Shares 30

Eiger BioPharma Plans to Raise up to USD25 Million in Public Offering of Shares 32

Eiger BioPharma Raises USD39.5 Million in Private Placement of Shares 33

Eiger BioPharma Sells Mydicar to Theragene Pharma 35

Eiger BioPharmaceuticals Inc, Key Competitors 36

Eiger BioPharmaceuticals Inc, Key Employees 37

Eiger BioPharmaceuticals Inc, Subsidiaries 38

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Eiger BioPharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.